The invention provides a method, which is developed and researched on the basis of high-flux sequencing, for detecting lymphoid blood cancer, including T/B series leukemia, lymphoma and myeloma minimal residual diseases. According to the method, internal references and House Keeping genes are added, a multiple PCR (Polymerase Chain Reaction) primer group with a UMB (Unique Molecular Barcode) is adopted to respectively carry out library construction on IGH(VDJ), IGH(DJ), IGK, IGL, TCR beta, TCR gamma, TCR delta, BCL1/IGH and BCL2/IGH; the obtained DNA library is sequenced through an Illumina HiSeq platform; a high-flux sequencing result is analyzed through bioinformatics. According to the method, while cancer cells are detected, new mutant cancer cells can be found, a high-flux sequencing technology is applied and combined with bioinformatics analysis, and the detection sensitivity of a MRD (Minimal Residual Disease) can detect at least one cancer cell in one million cells, i.e., 10<-6>(0.0001%). According to the method, the amount of cancer cells can be quantitatively analyzed to achieve an MRD detection purpose, and in addition, sequence mutation caused by base mismatch generatedby PCR amplification and a sequence reading error generated in a library sequencing process can be corrected.